We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 93.01%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
76
AnaptysBio
ANAB
$1.52B
$3.89M 0.03%
111,386
-5,825
-5% -$157K
ADMS
77
DELISTED
Adamas Pharmaceuticals
ADMS
$3.65M 0.03%
172,630
– –
ARAV
78
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.52M 0.03%
239,536
-37,230
-13% -$3.76M
TNXP icon
79
Tonix Pharmaceuticals
TNXP
$154M
– –
0
– –
AKTX
80
Akari Therapeutics
AKTX
$14.8M
$3.05M 0.02%
621
– –
NTRA icon
81
Natera
NTRA
$36.1B
$2.95M 0.02%
228,676
– –
OVID icon
82
Ovid Therapeutics
OVID
$426M
$2.86M 0.02%
333,333
– –
MDGL icon
83
Madrigal Pharmaceuticals
MDGL
$12.5B
$2.6M 0.02%
57,762
– –
RARX
84
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.6M 0.02%
177,952
– –
TRVN
85
DELISTED
Trevena, Inc.
TRVN
$2.42M 0.02%
1,520
– –
KPTI icon
86
Karyopharm Therapeutics
KPTI
$154M
$2.38M 0.02%
14,466
– –
NVAX icon
87
Novavax
NVAX
$1.19B
$2.28M 0.02%
100,000
– –
ARGX icon
88
argenx
ARGX
$55.2B
$2.26M 0.02%
100,000
– –
TRIL
89
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.13M 0.02%
413,697
– –
KRYS icon
90
Krystal Biotech
KRYS
$10.7B
$1.99M 0.02%
+200,000
New +$2.02M
DVAX
91
DELISTED
Dynavax Technologies
DVAX
$1.61M 0.01%
75,000
– –
JNCE
92
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.56M 0.01%
100,000
– –
IMDZ
93
DELISTED
Immune Design Corp.
IMDZ
$1.54M 0.01%
148,937
– –
VIRX
94
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.44M 0.01%
21,190
– –
CLLS
95
Cellectis
CLLS
$287M
$1.42M 0.01%
50,000
– –
MDWD icon
96
MediWound
MDWD
$189M
$1.21M 0.01%
32,286
– –
ABUS icon
97
Arbutus Biopharma
ABUS
$853M
$1.12M 0.01%
180,582
– –
AIXC
98
AIxCrypto Holdings Inc
AIXC
$14.2M
$980K 0.01%
22
+19
+633% +$1.33M
AFMD
99
DELISTED
Affimed
AFMD
$900K 0.01%
40,000
– –
ADAP
100
DELISTED
Adaptimmune Therapeutics
ADAP
$819K 0.01%
100,000
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Baker Bros. Advisors held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Baker Bros. Advisors added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Baker Bros. Advisors's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Baker Bros. Advisors fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Baker Bros. Advisors opened 9 new positions and closed 9 in Q3 2017.
  • Baker Bros. Advisors's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.